221 related articles for article (PubMed ID: 25926748)
1. Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence.
Sosale A; Saboo B; Sosale B
Diabetes Metab Syndr Obes; 2015; 8():189-96. PubMed ID: 25926748
[TBL] [Abstract][Full Text] [Related]
2. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
3. The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
Manoria PC; Chopra HK; Parashar SK; Dutta AL; Pinto B; Mullasari A; Prajapati S
Indian Heart J; 2013 Dec; 65(6):683-90. PubMed ID: 24407538
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
5. Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
Munigoti SP; Harinarayan CV
Indian J Endocrinol Metab; 2014 May; 18(3):283-7. PubMed ID: 24944919
[TBL] [Abstract][Full Text] [Related]
6. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
7. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies for managing dyslipidemia: treatment beyond statins.
Ling H; Burns TL; Hilleman DE
Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
[TBL] [Abstract][Full Text] [Related]
9. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Mitra A
Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
[TBL] [Abstract][Full Text] [Related]
10. PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.
Nikolic D; Castellino G; Banach M; Toth PP; Ivanova E; Orekhov AN; Montalto G; Rizzo M
Curr Pharm Des; 2017 Mar; 23(6):894-902. PubMed ID: 27719644
[TBL] [Abstract][Full Text] [Related]
11. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
12. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
13. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
14. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
Pershadsingh HA
Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
[TBL] [Abstract][Full Text] [Related]
15. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
17. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
18. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
19. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
[TBL] [Abstract][Full Text] [Related]
20. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
